Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

SHSE:600329 Stock Report

Market Cap: CN¥21.9b

Tianjin Pharmaceutical Da Ren Tang Group Past Earnings Performance

Past criteria checks 2/6

Tianjin Pharmaceutical Da Ren Tang Group has been growing earnings at an average annual rate of 12.7%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 5.3% per year. Tianjin Pharmaceutical Da Ren Tang Group's return on equity is 13.6%, and it has net margins of 11.9%.

Key information

12.7%

Earnings growth rate

12.7%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate5.3%
Return on equity13.6%
Net Margin11.9%
Next Earnings Update15 Aug 2024

Recent past performance updates

Recent updates

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Jul 05
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Fewer Investors Than Expected Jumping On Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329)

Apr 18
Fewer Investors Than Expected Jumping On Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329)

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Mar 18
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Revenue & Expenses Breakdown

How Tianjin Pharmaceutical Da Ren Tang Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:600329 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 248,1539732,533185
31 Dec 238,2229872,527185
30 Sep 238,4799912,562147
30 Jun 238,5631,1162,551150
31 Mar 238,5141,0632,490158
31 Dec 228,2498622,356153
30 Sep 227,1188371,910159
30 Jun 227,0427751,932150
31 Mar 226,9707561,929151
31 Dec 216,9087691,935161
30 Sep 216,9998461,911168
30 Jun 216,9548011,839169
31 Mar 216,7757051,843158
31 Dec 206,6046621,821149
30 Sep 206,7736571,934128
30 Jun 206,7516022,054126
31 Mar 206,8966052,126133
31 Dec 196,9946262,194133
30 Sep 196,8476062,174126
30 Jun 196,7805952,106118
31 Mar 196,4975782,043102
31 Dec 186,3595622,004101
30 Sep 186,0845172,01290
30 Jun 185,8145121,94387
31 Mar 185,8235161,82199
31 Dec 175,6894761,73379
30 Sep 175,7474331,74044
30 Jun 175,9524431,74829
31 Mar 176,0814381,7210
31 Dec 166,2434241,6920
30 Sep 166,8454671,5920
30 Jun 166,9974711,5640
31 Mar 167,1044521,6220
31 Dec 157,0814511,6330
30 Sep 157,0264361,7240
30 Jun 157,1143981,7450
31 Mar 157,1563751,7510
31 Dec 147,0873581,7050
30 Sep 146,6213721,6130
30 Jun 146,2673611,5550
31 Mar 146,1133361,5050
31 Dec 136,0103521,5080
30 Sep 135,7493071,4580

Quality Earnings: 600329 has high quality earnings.

Growing Profit Margin: 600329's current net profit margins (11.9%) are lower than last year (12.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 600329's earnings have grown by 12.7% per year over the past 5 years.

Accelerating Growth: 600329's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 600329 had negative earnings growth (-8.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).


Return on Equity

High ROE: 600329's Return on Equity (13.6%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.